BTIG Initiates Coverage On Spyre Therapeutics with Buy Rating, Announces Price Target of $32
Portfolio Pulse from Benzinga Newsdesk
BTIG analyst Julian Harrison has initiated coverage on Spyre Therapeutics (NASDAQ:SYRE) with a Buy rating and set a price target of $32.
December 20, 2023 | 1:46 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
BTIG initiated coverage on Spyre Therapeutics with a Buy rating and a price target of $32, indicating a positive outlook for the stock.
Analyst ratings, especially from reputable firms like BTIG, can significantly influence investor sentiment and stock prices in the short term. A Buy rating combined with a high price target suggests a strong positive outlook for Spyre Therapeutics, which could lead to an increase in stock price as investors react to the news.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100